Clincal study of interferon-alpha for prevention of relapse after transplantation in Ph+ALL patients with CD34+CD38-CD58- phenotype at diagnosis

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-14005546

Enrollment

Unknown

Registered

2014-11-24

Start date

2014-11-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute lymphoblastic leukemia

Interventions

case series:IFN-alpha

Eligibility

Sex/Gender

All

Age

14 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Ph positive ALL in CR1/CR2 and received allo-HSCT; 2. with CD34+CD38-CD58- phenotype at diagnosis; 3. in CR at 4.5 months after HSCT; 4. adults (14-60); 5. with written informed consent.

Exclusion criteria

Exclusion criteria: 1. active GVHD; 2. myelosuppression: WBC less than 2*10^9/L, ANC less than 1*10^9/L, PLT less than 50*10^9/L, HB less than 65g/L; 3. severe infection; 4. organ failure; 5. with prior history of DLI; 6. refuse to receive.

Design outcomes

Primary

Measure	Time frame
toxicity;	—

Countries

China

Contacts

Public ContactHUANG XIAO-JUN

sunyuqian83@163.com+86 010-88324577

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026